These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 37088083)

  • 21. Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy.
    Sterner RC; Sterner RM
    Front Immunol; 2022; 13():879608. PubMed ID: 36081506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.
    Sang W; Shi M; Yang J; Cao J; Xu L; Yan D; Yao M; Liu H; Li W; Zhang B; Sun K; Song X; Sun C; Jiao J; Qin Y; Sang T; Ma Y; Wu M; Gao X; Cheng H; Yan Z; Li D; Sun H; Zhu F; Wang Y; Zeng L; Li Z; Zheng J; Xu K
    Cancer Med; 2020 Aug; 9(16):5827-5838. PubMed ID: 32608579
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity.
    Jess J; Yates B; Dulau-Florea A; Parker K; Inglefield J; Lichtenstein D; Schischlik F; Ongkeko M; Wang Y; Shahani S; Cullinane A; Smith H; Kane E; Little L; Chen D; Fry TJ; Shalabi H; Wang HW; Satpathy A; Lozier J; Shah NN
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37295816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma.
    Liu M; Deng H; Mu J; Li Q; Pu Y; Jiang Y; Deng Q; Qian Z
    Cancer Sci; 2021 Jul; 112(7):2642-2651. PubMed ID: 33932067
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment.
    Gu T; Hu K; Si X; Hu Y; Huang H
    WIREs Mech Dis; 2022 Nov; 14(6):e1576. PubMed ID: 35871757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
    Abramson JS; Palomba ML; Gordon LI; Lunning MA; Wang M; Arnason J; Mehta A; Purev E; Maloney DG; Andreadis C; Sehgal A; Solomon SR; Ghosh N; Albertson TM; Garcia J; Kostic A; Mallaney M; Ogasawara K; Newhall K; Kim Y; Li D; Siddiqi T
    Lancet; 2020 Sep; 396(10254):839-852. PubMed ID: 32888407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD19 CAR-T Cell Therapy Induced Immunotherapy Associated Interstitial Pneumonitis: A Case Report.
    Sun Z; Xie C; Liu H; Yuan X
    Front Immunol; 2022; 13():778192. PubMed ID: 35154102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Managing the toxicities of CAR T-cell therapy.
    Neelapu SS
    Hematol Oncol; 2019 Jun; 37 Suppl 1():48-52. PubMed ID: 31187535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature.
    Zhao A; Zhao M; Qian W; Liang A; Li P; Liu H
    Front Immunol; 2022; 13():1063986. PubMed ID: 36713414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Toxicity after chimeric antigen receptor T-cell therapy : Overview and management of early and late onset side effects].
    Garcia Borrega J; Heindel K; Göreci Y; Warnke C; Onur OA; Kochanek M; Schub N; Ayuk F; Wichmann D; Böll B
    Internist (Berl); 2021 Jun; 62(6):611-619. PubMed ID: 34032877
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma.
    Wu J; Cao Y; Zhang Q; Liu W; Zhou X; Ming X; Meng F; Zhang Y; Li C; Huang L; Wei J; Zheng M; Zhang S; Zhang T; Zhu X; Wang N; Wang J; Wang G; Zhou J; Liu B; Xiao Y
    Front Immunol; 2022; 13():879983. PubMed ID: 35669773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid response in relapsed follicular lymphoma with massive chylous ascites to anti-CD19 CAR T therapy using Piggy Bac: A case report.
    Zhang Y; Lin Z; Zhang F; Chen X; Yang Y; Fu X; Li Z; Sun Y; Qian Q
    Front Immunol; 2022; 13():1007210. PubMed ID: 36532014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy.
    Gust J; Finney OC; Li D; Brakke HM; Hicks RM; Futrell RB; Gamble DN; Rawlings-Rhea SD; Khalatbari HK; Ishak GE; Duncan VE; Hevner RF; Jensen MC; Park JR; Gardner RA
    Ann Neurol; 2019 Jul; 86(1):42-54. PubMed ID: 31074527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy.
    Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH
    Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CAR T-Cell-Associated Neurotoxicity: Current Management and Emerging Treatment Strategies.
    Rivera AM; May S; Lei M; Qualls S; Bushey K; Rubin DB; Barra ME
    Crit Care Nurs Q; 2020; 43(2):191-204. PubMed ID: 32084062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of Preemptive Use of Tocilizumab on Chimeric Antigen Receptor T Cell Outcomes in Non-Hodgkin Lymphoma.
    De Philippis C; Mannina D; Giordano L; Costantini E; Marcheselli S; Mariotti J; Sarina B; Taurino D; Santoro A; Bramanti S
    Transplant Cell Ther; 2023 Jul; 29(7):429.e1-429.e6. PubMed ID: 36966874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Change in Patients' Perceived Cognition Following Chimeric Antigen Receptor T-Cell Therapy for Lymphoma.
    Barata A; Hoogland AI; Kommalapati A; Logue J; Welniak T; Hyland KA; Eisel SL; Small BJ; Jayani RV; Booth-Jones M; Oswald LB; Gonzalez BD; Kirtane KS; Jain MD; Mokhtari S; Chavez JC; Lazaryan A; Shah BD; Locke FL; Jim HSL
    Transplant Cell Ther; 2022 Jul; 28(7):401.e1-401.e7. PubMed ID: 35580732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma.
    Cortes-Bullich A; Perez A; Bachmeier C; Mhaskar R; Chavez JC; Shah B; Nishihori T; Khimani F; Lazaryan A; Davila ML; Locke FL; Jain MD
    Transplant Cell Ther; 2021 Sep; 27(9):768.e1-768.e6. PubMed ID: 34077811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Efficacy and safety of CD19 chimeric antigen receptor T cells for the treatment of 22 patients with B-cell lymphoma].
    Xiao X; Jiang YY; Cao YQ; Li Q; Jin X; Meng JX; Sui T; Li YM; Zhao MF
    Zhonghua Xue Ye Xue Za Zhi; 2019 Apr; 40(4):276-280. PubMed ID: 31104437
    [No Abstract]   [Full Text] [Related]  

  • 40. Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells.
    Park JH; Romero FA; Taur Y; Sadelain M; Brentjens RJ; Hohl TM; Seo SK
    Clin Infect Dis; 2018 Aug; 67(4):533-540. PubMed ID: 29481659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.